Hepatitis B virus-related hepatocellular carcinoma in young adults Efficacy of nationwide selective vaccination.
Hepatitis B vaccination in infancy was performed in Japan only when the mother was persistently infected since 1986 to 2016. The aim of the present study is to elucidate the results of vaccination for the prevention of hepatocellular carcinoma in the young adults. We studied the number of patients who had liver cancer and died since 1976 to 2017 using national database. Furthermore, we did nationwide survey focusing on patients with hepatitis B virus (HBV)-related hepatocellular carcinoma who were diagnosed under 40 years of age from 2007 to 2016. The national database showed that the number of deaths under the age of 40 decreased from 337 in 1986 to 61 in 2016. Among the 122 patients with hepatocellular carcinoma (HCC) who were registered in the survey, only three patients were born after the start of the vaccination in 1986. Liver cirrhosis, defined by a high Fib-4 index (≥3.25), was found in only 12.5% of the patients at the time of the survey. HCC was incidentally diagnosed in 85 of the 122 (69%) patients. More than 60% of the patients (54/88) were dead at the time of the study, which may be attributed to the delay in diagnosis. Selective vaccination was effective for the prevention of HBV-related HCC. On the other hand, many young adults who missed the chance of HB vaccination and HCC surveillance developed HCC and died. HBV screening in young adults and careful follow-up of infected patients are important to prevent HCC development.